Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs such as ischemic stroke and Acute Respiratory Distress Syndrome (ARDS).</li>
  <li>The company's lead asset, HLCM051 (MultiStem), is advancing towards late-stage clinical trials. A key potential catalyst is the planned application for conditional approval for ARDS in Japan, which could occur as early as 2025.</li>
  <li>Financially, the company is characterized by significant R&amp;D investment, leading to persistent net losses and negative cash flow. Its future is heavily dependent on clinical trial outcomes, regulatory approvals, and the ability to secure ongoing funding.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs such as ischemic stroke and Acute Respiratory Distress Syndrome (ARDS).
  The company's lead asset, HLCM051 (MultiStem), is advancing towards late-stage clinical trials. A key potential catalyst is the planned application for conditional approval for ARDS in Japan, which could occur as early as 2025.
  Financially, the company is characterized by significant R&amp;D investment, leading to persistent net losses and negative cash flow. Its future is heavily dependent on clinical trial outcomes, regulatory approvals, and the ability to secure ongoing funding.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Japan

Healios K.K. researches and develops iPSC Regenerative Medicine and Compound Drugs. The company researches for the development of treatment for Age-Related Macular Degeneration.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HEALIOS KK (4593 JP)

Primer: HEALIOS KK (4593 JP) - Dec 2025

HEALIOS K.K. is a clinical-stage biotechnology company at the forefront of regenerative medicine in Japan, focusing on high unmet medical needs...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)